Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction

Thrombosis Research

Volumn 118, Issue 2, 2006, Pages 189-197

  Cruden, Nicholas L M ^a   Graham, Catriona ^b   Harding, Scott A ^c   Ludlam, Christopher A ^a   Fox, Keith A A ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c WELLINGTON HOSPITAL   (New Zealand)

Author keywords

Fibrinolysis; Myocardial infarction; Reperfusion

Indexed keywords

ALTEPLASE; C REACTIVE PROTEIN; CD40 LIGAND; CREATINE KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT ANTIGEN; STREPTOKINASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HEMODYNAMIC MONITORING; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION; VENOUS BLOOD;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARBOXYPEPTIDASE U; CD40 LIGAND; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOLUBILITY; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33744543378     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.06.014     Document Type: Article

References (41)

1. Van de Werf F., Ardissino D., Betriu A., Cokkinos D.V., Falk E., Fox K.A., et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society Of Cardiology. Eur Heart J 24 (2003) 28-66
2. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329 (1993) 1615-1622
3. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342 (2000) 1792-1801
4. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., and Miller G.J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342 (1993) 1076-1079
5. Jansson J.H., Olofsson B.O., and Nilsson T.K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 88 (1993) 2030-2034
6. DeWood M.A., Spores J., Notske R., Mouser L.T., Burroughs R., Golden M.S., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303 (1980) 897-902
7. Barbash G.I., Hod H., Roth A., Miller H.I., Rath S., Zahav Y.H., et al. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 64 (1989) 1231-1235
8. Sinkovic A. Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction. Am Heart J 136 (1998) 406-411
9. Bouma B.N., Marx P.F., Mosnier L.O., and Meijers J.C. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 101 (2001) 329-354
10. Henry M., Aubert H., Morange P.E., Nanni I., Alessi M.C., Tiret L., et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97 (2001) 2053-2058
11. Silveira A., Schatteman K., Goossens F., Moor E., Scharpe S., Stromqvist M., et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84 (2000) 364-368
12. Juhan-Vague I., Morange P.E., Aubert H., Henry M., Aillaud M.F., Alessi M.C., et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22 (2002) 867-873
13. Redlitz A., Nicolini F.A., Malycky J.L., Topol E.J., and Plow E.F. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 93 (1996) 1328-1330
14. Mosnier L.O., von dem Borne P.A., Meijers J.C., and Bouma B.N. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 80 (1998) 829-835
15. Levi M., van der Poll T., and Buller H.R. Bidirectional relation between inflammation and coagulation. Circulation 109 (2004) 2698-2704
16. Nikfardjam M., Mullner M., Schreiber W., Oschatz E., Exner M., Domanovits H., et al. The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. J Intern Med 247 (2000) 341-345
17. Zairis M.N., Manousakis S.J., Stefanidis A.S., Papadaki O.A., Andrikopoulos G.K., Olympios C.D., et al. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J 144 (2002) 782-789
18. Prasad K.S., Andre P., Yan Y., and Phillips D.R. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 10 (2003) 356-361
19. Inwald D.P., McDowall A., Peters M.J., Callard R.E., and Klein N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92 (2003) 1041-1048
20. Lindmark E., Tenno T., and Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 20 (2000) 2322-2328
21. Andre P., Prasad K.S., Denis C.V., He M., Papalia J.M., Hynes R.O., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8 (2002) 247-252
22. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
23. de Lemos J.A., and Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 38 (2001) 1283-1294
24. Shah P.K., Cercek B., Lew A.S., and Ganz W. Angiographic validation of bedside markers of reperfusion. J Am Coll Cardiol 21 (1993) 55-61
25. Newby D.E., Wright R.A., Labinjoh C., Fox K.A., Boon N.A., and Webb D.J. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99 (1999) 1411-1415
26. Harding S.A., Sarma J., Josephs D.H., Cruden N.L., Din J.N., Twomey P.J., et al. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 109 (2004) 1926-1929
27. Zorio E., Castello R., Falco C., Espana F., Osa A., Almenar L., et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 122 (2003) 958-965
28. Hackworthy R.A., Vogel M.B., and Harris P.J. Relationship between changes in ST segment elevation and patency of the infarct-related coronary artery in acute myocardial infarction. Am Heart J 112 (1986) 279-284
29. Roe M.T., Ohman E.M., Maas A.C., Christenson R.H., Mahaffey K.W., Granger C.B., et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol 37 (2001) 9-18
30. Ribo M., Montaner J., Molina C.A., Arenillas J.F., Santamarina E., and Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 91 (2004) 1146-1151
31. Witherow F.N., Dawson P., Ludlam C.A., Fox K.A., and Newby D.E. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol 40 (2002) 961-966
32. Chandler W.L., Alessi M.C., Aillaud M.F., Henderson P., Vague P., and Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 96 (1997) 761-768
33. Marx P.F., Dawson P.E., Bouma B.N., and Meijers J.C. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 41 (2002) 6688-6696
34. Meijers J.C., Oudijk E.J., Mosnier L.O., Bos R., Bouma B.N., Nieuwenhuis H.K., et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 108 (2000) 518-523
35. Segev A., Hegele R.A., Lau H.K., Sparkes J.D., Teitel J.M., Chisholm R.J., et al. Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions. Thromb Res 114 (2004) 137-141
36. Paganelli F., Alessi M.C., Morange P., Maixent J.M., Levy S., and Vague I.J. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost 82 (1999) 104-108
37. Roux S., Christeller S., and Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 19 (1992) 671-677
38. Auer J., Berent R., Eber B., Tanaka A., Sano T., Namba M., et al. C-reactive protein in patients with acute myocardial infarction. Circulation 109 (2004) e20
39. Andre P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 (2002) 896-899
40. Furman M.I., Krueger L.A., Linden M.D., Barnard M.R., Frelinger III A.L., and Michelson A.D. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 43 (2004) 2319-2325
41. Johanson P., Jernberg T., Gunnarsson G., Lindahl B., Wallentin L., and Dellborg M. Prognostic value of ST-segment resolution- when and what to measure. Eur Heart J 24 (2003) 337-345